EDNRA: IHC Expression in Cancer and Radioligand Target Profile
EDNRA, endothelin receptor type A, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, EDNRA staining is highest in head and neck cancer (100% of samples positive), skin cancer (100% of samples positive) and pancreatic cancer (100% of samples positive). Evidence on whether EDNRA internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is EDNRA the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze EDNRA freeIs EDNRA a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EDNRA IHC staining by cancer type
Protein expression of EDNRA across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 0.67 | High | 100% |
| Skin Cancer | 0.64 | High | 100% |
| Pancreatic Cancer | 0.64 | High | 100% |
| Thyroid Cancer | 0.58 | High | 100% |
| Cervical Cancer | 0.58 | High | 100% |
| Ovarian Cancer | 0.58 | High | 100% |
| Glioma | 0.56 | High | 83% |
| Gastric Cancer | 0.52 | High | 89% |
| Colorectal Cancer | 0.50 | Medium | 100% |
| Breast Cancer | 0.50 | Medium | 92% |
| Lymphoma | 0.47 | Medium | 100% |
| Endometrial Cancer | 0.47 | Medium | 83% |
| Lung Cancer | 0.47 | Medium | 80% |
| Melanoma | 0.39 | Medium | 91% |
| Testicular Cancer | 0.39 | Medium | 83% |
| Bladder Cancer | 0.39 | Medium | 75% |
| Prostate Cancer | 0.37 | Medium | 78% |
| Neuroendocrine Tumors | 0.33 | Medium | 75% |
| Kidney Cancer | 0.33 | Medium | 64% |
| Liver Cancer | 0.30 | Medium | 55% |
Is EDNRA internalized?
Uncertain. Insufficient literature found.
EDNRA clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for EDNRA yet. Search ClinicalTrials.gov for EDNRA trials.
EDNRA normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EDNRA in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EDNRA gene essentiality (DepMap)
CRISPR knockout effect across 1254 cancer cell lines: 0.12 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · HER2 (ERBB2)
See all radioligand therapy targets in head and neck cancer.
See how EDNRA ranks against 15,000 targets for your indication.
Analyze EDNRA freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.